Veterans Affairs Medical Center, Diabetes Endocrinology Research Center, and Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52246
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Nutritional supplementation with dehydroepiandrosterone (DHEA) may be a candidate for treating diabetes-induced vascular and neural dysfunction. DHEA is a naturally occurring adrenal androgen that has antioxidant properties and is reportedly reduced in diabetes. Using a prevention protocol, we found that dietary supplementation of streptozotocin-induced diabetic rats with 0.1, 0.25, or 0.5% DHEA caused a concentration-dependent prevention in the development of motor nerve conduction velocity and endoneurial blood flow impairment, which are decreased in diabetes. At 0.25%, DHEA significantly prevented the diabetes-induced increase in serum thiobarbituric acid-reactive substances and sciatic nerve conjugated diene levels. This treatment also reduced the production of superoxide by epineurial arterioles of the sciatic nerve. DHEA treatment (0.25%) significantly improved vascular relaxation mediated by acetylcholine in epineurial vessels of diabetic rats. Sciatic nerve Na+-K+-ATPase activity and myoinositol content was also improved by DHEA treatment, whereas sorbitol and fructose content remained elevated. These studies suggest that DHEA, by preventing oxidative stress and perhaps improving sciatic nerve Na+-K+-ATPase activity, may improve vascular and neural dysfunction in diabetes.
diabetic neuropathy; vascular reactivity; oxidative stress; superoxide
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DIABETIC NEUROPATHY is a multifactorial problem with a unique etiology. It has been described by some investigators to be a disease of the vasculature leading to nerve ischemia and altered nerve function (9, 11, 12, 14, 43, 45, 56, 59). Other investigators have proposed that diabetic neuropathy is caused by metabolic defects associated with an increased flux of glucose through the aldose reductase pathway and depletion of intracellular myoinositol levels, leading to a defect in Na+-K+-ATPase activity and an alteration of signal transduction pathways in the nerve (23, 31, 36). Our studies suggest that vascular dysfunction of epineurial vessels and reduction in endoneurial blood flow (EBF) is responsible for the early stages of diabetic neuropathy (17). In addition, we have shown that oxidative stress, likely due to the generation of superoxide, causes vascular dysfunction in epineurial arterioles and accompanies the reduction in EBF, and these abnormalities precede the slowing of motor nerve conduction velocity (MNCV) (18, 19).
Because of the multiple abnormalities contributing to the etiology of diabetic neuropathy, it is impractical to attempt to treat this disorder by correcting each of these individually. Therefore, investigators are faced with the problem of determining the vascular or metabolic defects that have the greatest impact on the development of diabetic neuropathy and then designing strategies to treat the more relevant defects. In this regard, we have found that treating diabetic rats with antioxidants corrects the vascular defects in epineurial vessels and improves neural function (18, 19). We would now like to identify a safe and efficacious antioxidant therapy that will correct the vascular and neural dysfunctions induced by diabetes. One disadvantage of current antioxidant therapies is that a large concentration of antioxidant is usually required to achieve a significant benefit, which may result in undesired side effects. In addition, the method of delivery of some antioxidants is impractical for therapeutic use in patients (10). However, dehydroepiandrosterone (DHEA) may be a compound that will circumvent these problems. DHEA is a naturally occurring adrenal steroid that can be provided as a nutritional supplement. Moreover, DHEA has been shown to have antioxidant properties and is reported by some investigators to be decreased in diabetes and aging (4, 5, 7, 41, 42, 52). In these studies, we demonstrate that treating diabetic rats with 0.25% DHEA in the diet for 4-5 wk blocks the diabetes-induced increase in superoxide production in epineurial vessels and prevents the development of vascular and neural dysfunction.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials. Unless stated otherwise, all chemicals used in these studies were obtained from Sigma Chemical (St. Louis, MO).
Animals.
Male Sprague-Dawley rats (Harlan Sprague Dawley, Indianapolis, IN)
8-9 wk of age were used for these studies. The animals were housed
in a certified animal care facility, and food [Harlan Teklad, no. 7001 (meal form), Madison, WI] and water were provided ad libitum. All
institutional and National Institutes of Health guidelines for use of
animals were followed. Diabetes was induced by intravenously injecting
streptozotocin (60 mg/kg in 0.9% NaCl, adjusted to pH 4.0 with 0.2 M
sodium citrate). Control rats were injected with vehicle alone. The
rats were anesthetized with methoxyflurane before injection. Diabetes
was verified 48 h later by evaluating blood glucose levels with
the use of glucose oxidase reagent strips (Lifescan, Milpitas, CA).
Rats having a blood glucose level 300 mg/dl (16.7 mM) were considered
to be diabetic. At that time, the diabetic rats were randomly divided
into four groups, three to receive 0.1%, 0.25%, or 0.5% DHEA
(5-androsten-3
-ol-17-one,dehydroepiandrosterone; Steraloids,
Newport, RI) in the diet (based on the average amount of food consumed
per day by control and diabetic rats, the amount of DHEA received from
the three diets was 0.05, 0.125, and 0.25 g · day
1 · kg
1
rat and 0.075, 0.1875, and 0.375 g · day
1 · kg
1
rat for control and diabetic rats, respectively). The fourth group
received an unmodified diet. Control rats were also fed an unmodified
diet. Additional control rats were fed a diet containing 0.25 or 0.5%
DHEA. Dietary treatments with DHEA were started on the day when
hyperglycemia was verified. All studies were conducted ~4-5 wk
after the verification of diabetes.
MNCV. As previously described (14-16, 50), MNCV was determined by use of a noninvasive procedure in the sciatic-posterior tibial conducting system in a temperature controlled environment.
EBF.
Immediately after determination of MNCV, sciatic nerve endoneurial
nutritive blood flow was determined using the hydrogen clearance
method as described by Cameron et al. (12) and
adapted by our laboratory (54). The hydrogen clearance
data were fitted by computer to a mono- or biexponential curve by means
of commercial software (Prism; GraphPad, San Diego, CA). Nutritive
blood flow (ml · min1 · 100 g
1) was calculated using the equation described by
Young (62), and vascular conductance
(ml · min
1 · 100 g
1 · mmHg
1) was
determined by dividing nutritive blood flow by the average mean
arterial blood pressure.
Vascular reactivity.
Videomicroscopy was used to investigate in vitro vasodilatory
responsiveness of epineurial arterioles supplying the region of the
sciatic nerve (branches of the superior gluteal and internal pudendal
arteries) to acetylcholine (from 104 to 10
8
mol/l) or sodium nitroprusside (10
4 mol/l), as previously
described (54). In separate studies, the direct effects of
DHEA (from 10
6 to 10
10 mol/l) and
17
-estradiol (from 10
6 to 10
10 mol/l) on
vasodilation in vitro were examined using videomicroscopy. DHEA or
17
-estradiol was dissolved in ethanol and diluted in Krebs-Henseleit
physiological saline solution (54).
Detection of superoxide. Hydroethidine (Molecular Probes, Eugene, OR), an oxidative fluorescent dye, was used to evaluate in situ levels of superoxide in epineurial vessels, as described previously (17-19). Hydroethidine is permeable to cells and in the presence of superoxide is oxidized to fluorescent ethidium bromide, when it is trapped by intercalating with DNA. This method provides sensitive detection of superoxide in situ. Superoxide levels were also measured in the aorta by lucigenin-enhanced chemiluminescence as described previously (17-19, 38).
Sciatic nerve Na+-K+-ATPase activity and sorbitol, fructose, and myoinositol content. The left sciatic nerve was removed, desheathed, and divided into four samples for determination of Na+-K+-ATPase activity, conjugated diene level, glutathione level, and sorbitol, fructose, and myoinositol content as previously described (17-19).
Additional biological parameters. Sciatic nerve glutathione, serum thiobarbituric acid-reactive substances (TBARS), and sciatic nerve conjugated diene levels were determined as additional markers of oxidative stress. Sciatic nerve glutathione levels were determined according to Lou et al. (34). Tissue was weighed and homogenized in 1 ml of cold 10% trichloroacetic acid and centrifuged for 15 min at 1,000 g. The supernatant (100 µl) was mixed with 0.89 ml of 1.0 M Tris, pH 8.2, and 0.02 M EDTA. Next, 10 µl of dithionitrobenzene were added, and change in absorbance was measured at 412 nm. A glutathione standard curve (100-500 ng) was performed for each assay. The data were recorded as micrograms per milligram wet weight. TBARS level in serum was determined by the method of Mihara et al. (37), as modified by Siman and Eriksson (51). Briefly, 200 µl of serum were boiled in 0.75 ml of phosphoric acid (0.19 M), 0.25 ml of thiobarbituric acid (0.42 mM), and 0.3 ml of water for 60 min. Then, the samples were precipitated with methanol-NaOH and centrifuged for 5 min. The supernatant was measured fluorometrically at excitation wavelength of 532 nm and emission wavelength of 553 nm. Standards were prepared by the acid hydrolysis of 1,1,3,3-tetraethoxypropane. The data were reported as micrograms per milliliter of serum. Sciatic nerve-conjugated diene levels were determined according to the method of Recknagel and Ghoshal (46) and Low and Nickander (35). Briefly, a segment of the sciatic nerve was extracted with chloroform and methanol. The lipid extract was evaporated and redissolved in 1 ml of cyclohexane. Conjugated diene levels were determined by measuring the absorbance at 233 nm with extraction blanks used as references. An extinction coefficient of 2.52 × 104 M was used to determine the amount of conjugated diene present. The data were reported as micromoles per milligram of wet weight. Serum free fatty acid and triglyceride levels were determined using commercial kits from Roche Diagnostics (Mannheim, Germany) and Sigma Chemical (St. Louis, MO), respectively.
Determination of serum DHEA and estrogen. Assays for serum level of DHEA and estrogen were performed using RIA assay kits from Diagnostic Systems Laboratories (Webster, TX) according to the manufacturer's instructions.
Data analysis. The results are presented as means ± SE. Comparisons between the groups for MNCV, EBF, sciatic nerve Na+-K+-ATPase activity, sciatic nerve sorbitol, fructose, and myoinositol content, serum TBARS, sciatic nerve conjugated diene, serum free fatty acid and triglyceride levels, and lens and sciatic nerve glutathione levels were conducted. After data transformation, a one-way ANOVA was applied with a Newman-Keuls test for multiple comparisons (Prism software; GraphPad, San Diego, CA). Dose-response curves for acetylcholine-induced relaxation were compared using a two-way repeated-measures ANOVA with autoregressive covariance structure using the proc mixed program of SAS (17-19, 54). Whenever significant interactions were noted, specific treatment-dose effects were analyzed using a Bonferroni adjustment. A P value <0.05 was considered significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Change in body weight, blood glucose level, and serum DHEA and
estrogen levels.
Data in Table 1 show the change in body
weight for control and diabetic rats treated with or without DHEA for
the period of the study. At the time of experimentation, blood glucose
was significantly increased in diabetic rats treated with or without DHEA. There was no difference in blood glucose level between diabetic rats and diabetic rats treated with DHEA. Data in Fig.
1 demonstrate that feeding diabetic rats
0.1-0.5% DHEA caused a concentration-dependent increase in DHEA
level in the serum. At 0.25 and 0.5%, the increase in DHEA in the
serum was significant compared with that in control rats. The level of
estrogen in the serum was also increased, but the change from control
rats was not significant. Basal serum DHEA and estrogen levels in
control and nontreated diabetic rats were similar. Measurement of serum
free fatty acid and triglyceride levels revealed that treating diabetic
rats with DHEA does not change the diabetes-induced increase in free
fatty acid or triglyceride levels (data not shown).
|
|
Sciatic nerve
Na+-K+-ATPase
activity and sorbitol, fructose, and myoinositol content.
Data in Table 2 demonstrate that diabetes
caused a 30% decrease in sciatic nerve
Na+-K+-ATPase activity. Treating diabetic rats
with 0.25 or 0.5% DHEA caused a significant increase in
Na+-K+-ATPase activity compared with control
and untreated diabetic rats. Data in Table 2 also demonstrate that
diabetes caused a significant increase in fructose content and a
decrease in myoinositol level in the sciatic nerve. Treating diabetic
rats with 0.25 or 0.5% DHEA prevented the decrease in myoinositol
content in the sciatic nerve.
|
Evaluation of oxidative stress.
Data in Table 3 demonstrate that the
glutathione level in the sciatic nerve was decreased by diabetes, but
this difference was not statistically significant. Treating diabetic
rats with 0.25 or 0.5% DHEA tended to prevent the decrease in the
sciatic nerve glutathione level. Diabetes caused a significant increase in the sciatic nerve conjugated diene level, which was prevented by
treating diabetic rats with 0.25 or 0.5% DHEA. Diabetes also caused a
significant increase in serum TBARS, which was prevented by treating
diabetic rats with 0.25% DHEA.
|
|
EBF and MNCV.
Data in Fig. 3 demonstrate that treating
diabetic rats with 0.25 or 0.5% DHEA prevented the decrease in EBF
compared with untreated diabetic rats. Data in Fig.
4 demonstrate that treating diabetic rats
with 0.25% DHEA significantly prevented the development of the
diabetes-induced slowing in MNCV.
|
|
Arteriolar vascular reactivity.
As demonstrated in Fig. 5, diabetes
caused a significant decrease (P < 0.05) in
acetylcholine (from 104 to 10
8
mol/l)-mediated vascular relaxation in epineurial arterioles of the
sciatic nerve. Treating diabetic rats with 0.25% DHEA significantly prevented the development of the diabetes-induced impairment in acetylcholine-mediated vascular relaxation (P < 0.05).
In contrast, treating diabetic rats with 0.1 or 0.5% DHEA was less
effective. Treating control rats with 0.25 or 0.5% DHEA had no effect
on acetylcholine-mediated vasodilation (data not shown). Maximal endothelium-independent vasodilation induced by sodium nitroprusside (10
4 M) was not affected by diabetes or by treatment of
diabetic rats with 0.25% DHEA [100.1 ± 3.3, 90.0 ± 4.8, and 91.1 ± 2.8% in control rats (n = 16), untreated diabetic rats (n = 14), and
diabetic rats treated with 0.25% DHEA (n = 36),
respectively]. Baseline diameters of the vessels used in these studies
were not different for control, untreated diabetic or diabetic rats
treated with DHEA (data not shown).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Previously (54), we demonstrated that the diabetes-induced decrease in endoneurial blood flow and impairment of acetylcholine-induced vasodilation of epineurial arterioles of the sciatic nerve precede the slowing of MNCV and the decrease in Na+-K+-ATPase activity in the sciatic nerve. In addition, we showed (17) that the generation of superoxide in epineurial arterioles of the sciatic nerve accompanies the diabetes-induced impairment in vasodilation. In the present studies, we have demonstrated that treating streptozotocin-induced diabetic rats with 0.25% DHEA partially prevented the diabetes-induced production of superoxide in epineurial vessels of the sciatic nerve, slowing of MNCV, reduction in endoneurial blood flow, and impairment of acetylcholine-mediated vascular relaxation in epineurial arterioles of the sciatic nerve.
DHEA and its sulfated metabolite DHEA-S are the most abundant
circulating adrenal steroids in humans. Plasma concentrations of DHEA
peak in the third decade and fall gradually thereafter to levels of
20% of peak by the eighth decade (58). Circulating levels
of DHEA are significantly lower in rodents than in humans (61). In these studies, feeding rats a diet containing
0.25% DHEA resulted in a large increase in DHEA in serum (~300 nM). The baseline level of DHEA in humans is ~10 nM (57).
However, when DHEA supplements ranging from 50-2,250 mg/day are
taken, the DHEA level in serum has been shown to increase to as high as
230 nM (54). Even though the amount of DHEA required in
the diet of diabetic rats was high to achieve an effect on vascular and
neural function, the amount of DHEA in the serum of diabetic rats fed a
diet containing 0.25% DHEA is achievable in humans when oral
supplements are taken (57). Apart from its role as a
precursor to androgens and estrogens, other biological effects of DHEA
have been described (21). DHEA has well characterized effects on satiety, obesity, and diabetes in rodents (47).
It may also affect satiety, obesity, and cardiovascular disease in humans, although these reports remain controversial and the mechanisms of these effects remain unclear (6, 13, 30). The
reciprocal relationship of plasma DHEA concentration in age-related
disorders and diabetes mellitus has prompted exploration of a possible
role for DHEA in these disorders. In this regard, it has been shown that DHEA and its metabolites can prevent/reduce hyperglycemia in the
ZDF/Gmi fa/fa rat and the C57BL/KsJ db/db mouse
(8, 15, 16). In those studies, treatment with DHEA and/or
metabolites began before the onset of hyperglycemia and, in the
db/db mouse, was proposed to maintain islet integrity
(8, 15, 16). Moreover, Dillon et al. (20)
have demonstrated that DHEA-S acts on -cells to increase
glucose-stimulated insulin secretion through a transcriptional mechanism. However, in streptozotocin-induced diabetic rats, DHEA treatment did not cause a decrease in plasma glucose levels
(2). In the latter study, as well as in ours, treatment
with DHEA was not initiated until after the onset of hyperglycemia
(2). In contrast, in the studies using the ZDF rats and
db/db mice, both genetic diabetic animal models, DHEA
treatment was begun before the development of hyperglycemia and
-cell dysfunction (8, 15, 16). Therefore, it is
unlikely that in the streptozotocin-induced diabetic rat, which is a
model of
-cell injury and death, that DHEA is capable of improving
hyperglycemia by modifying glucose uptake.
One possible mechanism for the action of DHEA is through its conversion
to estradiol. This is supported by studies of hypertensive rabbits
treated with 0.3% DHEA in the diet. About 50% of the DHEA effect in
reducing atherosclerosis in this animal model was due to the increased
production of estradiol (29). Estrogens have a wide array
of biological effects, targeting both genomic and nongenomic mechanisms
(39). Recent studies have shown that estrogen can increase
endothelial nitric oxide synthase (eNOS) expression and/or activity,
leading to increased vascular relaxation (22, 48, 53, 55,
63). We have recently shown (33) that DHEA can also
stimulate eNOS activity in vascular endothelial cells by a specific G
protein-coupled plasma membrane receptor. This effect of DHEA on
endothelial cell nitric oxide production was independent of the action
of estrogen. In the present studies, feeding rats a diet containing
0.1-0.5% DHEA caused a concentration-dependent increase in
estrogen in circulation. However, the increase in estrogen level in the
serum was not statistically significant compared with the level in
control rats. It is unlikely that the effect of DHEA in improving
diabetes-induced impairment in vascular relaxation was due to an
increase in estrogen levels. We demonstrated that estrogen, at a
concentration similar to estrogen levels found in rats fed 0.25% DHEA
(~0.5 nM), did not induce vasodilation in epineurial vessels in
vitro; 17-estradiol or DHEA at 1 nM caused only a 2 or 11%
vasodilation, respectively. In another study, estrogen has been shown
to downregulate mRNA expression of
Na+-K+-ATPase
1-subunit in renal tissue
(32). This finding is inconsistent with our studies and
with those by Aragno et al. (2), which demonstrated that
DHEA treatment of diabetic rats increased
Na+-K+-ATPase activity in the sciatic nerve and
renal tissue, respectively. These studies argue against a role
for increased estrogen production from DHEA in the regulation of
Na+-K+-ATPase activity. However, we cannot rule
out a role for chronic increased levels of estrogen in DHEA-fed rats on
vascular and neural function. Additional studies will be necessary
using an aromatase inhibitor such as fadrozole and perhaps estradiol
supplementation to address this issue (24).
DHEA has been shown to have antioxidant properties (4, 5, 7, 41,
42, 52). Our previous studies (18, 19) have
demonstrated that increased oxidative stress contributes to neural
dysfunction in diabetes. In streptozotocin-treated diabetic rats,
treatment with DHEA was shown to reduce serum and tissue TBARS and
fluorescent chromolipids (5). DHEA treatment also restored
glutathione levels in the liver and kidney as well as the enzymatic
activity of catalase, superoxide dismutase, and glutathione peroxidase
(5). DHEA has been demonstrated to prevent damage induced
by acute and chronic hyperglycemia and to restore the redox state in
ganglion synaptosomes isolated from diabetic rats (1,
3-5). In their recent study, Aragno et al. (2) reported that treatment of streptozotocin-induced diabetic rats with
DHEA might delay the progression of diabetic kidney disease by reducing
the inflammatory response to oxidative stress. In the present studies,
0.25% DHEA treatment of diabetic rats clearly prevented oxidative
stress. Compared with our previous studies, 0.25% DHEA treatment was
almost as effective as -lipoic acid in preventing superoxide
formation in vascular tissue and other markers of oxidative stress in
streptozotocin-induced diabetic rats, as well as preventing impairment
in endoneurial blood flow, vascular function, and MNCV
(18). Potential sources for increased superoxide
production in diabetes include the mitochondria, NAD(P)H oxidase,
xanthine oxidase, and nitric oxide synthase. Schwartz and Pashko
(49, 50) demonstrated that administering DHEA to laboratory mice and rats inhibits development of experimental tumors.
They suggested that the antiproliferative and tumor-preventive effects
of DHEA were due to inhibition of glucose-6-phosphate dehydrogenase and
the pentose phosphate pathway. This pathway is an important source of
NADPH, a critical reductant for many biochemical reactions that
generate oxygen free radicals (49, 50). Therefore, one
possible mechanism for the DHEA-mediated decrease in oxidative stress
is by reducing NADPH levels and thus generation of superoxide by
NAD(P)H oxidase.
Another mechanism by which DHEA treatment may be improving neural
function is through preventing the decrease in sciatic nerve Na+-K+-ATPase activity and myoinositol content.
Greene and coinvestigators [(24, 27) and Kim et al.
(31)] have demonstrated that the diabetes-induced decrease in sciatic nerve Na+-K+-ATPase
activity and the reciprocal increase in sorbitol levels and decrease in
myoinositol content are linked to nerve dysfunction. It should be noted
that, in contrast to previous studies, the diabetes-induced decrease in
Na+-K+-ATPase activity in these studies did not
reach statistical significance. Nonetheless, our studies demonstrated
that 0.25 and 0.5% DHEA treatment of diabetic rats prevented the 30%
diabetes-induced decrease in sciatic nerve
Na+-K+-ATPase activity and myoinositol content.
DHEA treatment was more effective than -lipoic acid, and as
effective as treatment with aldose reductase inhibitors, in preventing
the decrease in sciatic nerve Na+-K+-ATPase
activity (19, 25, 27). Aragno et al. (2)
demonstrated that treating diabetic rats with DHEA significantly
prevented the diabetes-induced decrease in renal
Na+-K+-ATPase activity. These investigators
concluded that the reduction in 5- and
15-hydroperoxyeicosatetraenoic (HPETE) acid and 4-hydroxynonenal levels in the kidney of diabetic rats treated with DHEA
contributed to the improvement of Na+-K+-ATPase
activity. Both 5- and 15-HPETE are potent inhibitors of Na+-K+-ATPase activity (2). In
our present studies, 0.25 and 0.5% DHEA treatment of diabetic rats
resulted in an increase in sciatic nerve
Na+-K+-ATPase activity. The mechanism
responsible for this effect of DHEA is not clear. It is unlikely to be
due to preventing the redox imbalance induced by diabetes, because
sciatic nerve sorbitol and fructose levels were still elevated in
DHEA-treated diabetic rats. It is possible that improvement in
oxidative stress caused by DHEA treatment or an increase in expression
of Na+-K+-ATPase in diabetic rats could have
contributed to an increase in Na+-K+-ATPase
activity. Liu and Dillon (33) have demonstrated, by use of
cultured bovine aorta endothelial cells, that DHEA, through binding to
a G protein-coupled receptor, activates mitogen-activated protein
kinase and tyrosine kinase activity. It has been shown by several
laboratories (28, 40, 44) that activation of the tyrosine
kinase and/or mitogen-activated protein kinase pathway increases
Na+-K+-ATPase activity, likely by increasing
protein expression. Therefore, activation of these kinases may be
responsible for the increase in Na+-K+-ATPase
activity in sciatic nerve of diabetic rats treated with DHEA.
Treating diabetic rats with 0.1% DHEA generally had little effect in preventing oxidative stress and vascular and neural dysfunction, whereas treatment with 0.5% DHEA, with exception of its effect on endoneurial blood flow and sciatic nerve Na+-K+-ATPase activity, appeared to exacerbate oxidative stress and some of the diabetes-induced vascular and neural defects compared with 0.25% DHEA treatment, suggesting that, at higher doses, DHEA may be pathogenic. As demonstrated in Table 1, diabetic rats fed a diet containing 0.5% DHEA had a tendency to lose more weight than diabetic rats fed a diet containing 0.25% DHEA. However, treating nondiabetic rats with 0.25 or 0.5% DHEA appeared to have no adverse effects on vascular or neural function or metabolic measurements (data not shown). We do not have a straightforward explanation why treatment of diabetic rats with 0.5% DHEA appeared to be beneficial in some respects but less so with respect to other vascular and neural functions. Clearly, 0.5% DHEA improved sciatic nerve endoneurial blood flow and Na+-K+-ATPase activity. In contrast, vascular dysfunction, MNCV, and markers of oxidative stress were not improved to the same extent with 0.5% DHEA as those seen with dietary supplementation of diabetic rats with 0.25% DHEA. One possible interpretation is that, at higher doses, DHEA, or perhaps one of its metabolites, may have direct, deleterious effects on neural and/or vascular function. Some of the ambiguity may also be due to the increased formation of estrogen that occurs with supplementation of the diet with 0.5% DHEA. It is possible that estrogen may be improving endoneurial blood flow by affecting vascular function of the endoneurial blood vessels in the sciatic nerve. Another possible explanation for the increase in endoneurial blood flow in diabetic rats fed a diet containing 0.5% DHEA, is that DHEA treatment could be causing an increase in nitric oxide production by the endothelium, leading to improved vascular relaxation. This is supported by studies by Liu and Dillon (33), which have demonstrated that DHEA activates eNOS by a specific plasma membrane receptor coupled to G proteins in cultured bovine aorta endothelial cells. Nonetheless, our studies suggest that the proper dosage of DHEA is important for treatment of diabetes-induced vascular and neural dysfunction. This may be one reason for some of the inconsistent results obtained with DHEA treatment in some studies (60).
In summary, the beneficial effects of DHEA that we observed on vascular and neural function are dose dependent. The administration of 0.25% DHEA in the diet of diabetic rats, likely through reducing oxidative stress, prevented vascular and neural dysfunction, suggesting that further study of the potential benefits of DHEA in preventing diabetic complications is warranted.
![]() |
ACKNOWLEDGEMENTS |
---|
This publication was made possible by Grants DK-25295, AG-18928, and DK-58005 from the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: M. A. Yorek, 3 E 17 Veteran Affairs Medical Center, Iowa City, IA 52246 (E-mail: myorek{at}icva.gov).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
July 30, 2002;10.1152/ajpendo.00173.2002
Received 25 February 2002; accepted in final form 23 July 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Aragno, M,
Brignardello E,
Tamagno E,
Gatto V,
Danni O,
and
Boccuzzi G.
Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats.
J Endocrinol
155:
233-240,
1997
2.
Aragno, M,
Parola S,
Brignardello E,
Manti R,
Betteto S,
Tamagno E,
Danni O,
and
Boccuzzi G.
Oxidative stress and eicosanoids in the kidneys of hyperglycemic rats treated with dehydroepiandrosterone.
Free Radic Biol Med
31:
935-942,
2001[ISI][Medline].
3.
Aragno, M,
Parola S,
Brignardello E,
Mauro E,
Tamagno E,
Manti R,
Danni O,
and
Boccuzzi G.
Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats.
Diabetes
49:
1924-1931,
2000[Abstract].
4.
Aragno, M,
Parola S,
Tamagno E,
Brignardello E,
Manti R,
Danni O,
and
Boccuzzi G.
Oxidative derangement in rat synaptosomes induced by hyperglycaemia: restorative effect of dehydroepiandrosterone treatment.
Biochem Pharmacol
60:
389-395,
2000[ISI][Medline].
5.
Aragno, M,
Tamagno Gatto VE,
Brignardello E,
Parola S,
Danni O,
and
Boccuzzi G.
Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress.
Free Radic Biol Med
26:
1467-1474,
1999[ISI][Medline].
6.
Barrett-Connor, E,
and
Goodman-Gruen D.
The epidemiology of DHEAS and cardiovascular disease.
Ann NY Acad Sci
774:
259-270,
1995[Abstract].
7.
Bastianetto, S,
Ramassamy C,
Poirier J,
and
Quirion R.
Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage.
Brain Res
66:
35-41,
1999.
8.
Byrne, JJ,
and
Bradlow HL.
DHEA-PC slows the progression of type 2 diabetes (non-insulin-dependent diabetes mellitus) in the ZDF/Gmi-fa/fa rat.
Diabetes Technol Ther
3:
221-224,
2001[Medline].
9.
Cameron, NE,
and
Cotter MA.
The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications.
Diabetes Metab Rev
10:
189-224,
1994[ISI][Medline].
10.
Cameron, NE,
and
Cotter MA.
Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.
Diabetes Res Clin Pract
45:
137-146,
1999[ISI][Medline].
11.
Cameron, NE,
Cotter MA,
Archibald V,
Dines KC,
and
Maxfield EK.
Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.
Diabetologia
37:
449-459,
1994[ISI][Medline].
12.
Cameron, NE,
Cotter MA,
and
Low PA.
Nerve blood flow in early experimental diabetes in rats: relation to conduction defects.
Am J Physiol Endocrinol Metab
261:
E1-E8,
1991
13.
Clore, J.
Dehydroepiandrosterone and body fat.
Obes Res
3:
613S-616S,
1995[Abstract], 1995.
14.
Cohen, RA.
Dysfunction of vascular endothelium in diabetes mellitus.
Circulation
87:
67-76,
1993[ISI].
15.
Coleman, DL,
Leiter EH,
and
Applezweig N.
Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/KsJ-db/db).
Endocrinology
115:
239-243,
1984[Abstract].
16.
Coleman, DL,
Leiter EH,
and
Schwizer RW.
Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes mice.
Diabetes
31:
830-836,
1982[Abstract].
17.
Coppey, LJ,
Davidson EP,
Dunlap JA,
Lund DD,
and
Yorek MA.
Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that provide circulation to the sciatic nerve.
Int J Exp Diabetes Res
1:
131-143,
2000[Medline].
18.
Coppey, LJ,
Gellett JS,
Davidson EP,
Dunlap JA,
Lund DD,
Salvemini D,
and
Yorek MA.
Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular function of epineurial arterioles of the sciatic nerve.
Br J Pharmacol
134:
121-129,
2001.
19.
Coppey, LJ,
Gellett JS,
Davidson EP,
Dunlap JA,
Lund DD,
and
Yorek MA.
Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.
Diabetes
50:
1927-1937,
2001
20.
Dillon, JS,
Yaney GC,
Zhou Y,
Voilley N,
Bowen S,
Chipkin S,
Bliss CR,
Schultz V,
Schuit FC,
Prentki M,
Waxman DJ,
and
Corkey BE.
Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells.
Diabetes
49:
2012-2020,
2000[Abstract].
21.
Ebeling, P,
and
Koivisto VA.
Physiological importance of dehydroepiandrosterone.
Lancet
343:
1479-1481,
1994[ISI][Medline].
22.
Gonzales, RJ,
Walker BR,
and
Kanagy NL.
17-Estradiol increases nitric-oxide-dependent dilation in rat pulmonary arteries and thoracic aorta.
Am J Physiol Lung Cell Mol Physiol
280:
L555-L564,
2001
23.
Greene, DA,
De Jesus PV,
and
Winegrad AI.
Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes.
J Clin Invest
55:
1326-1336,
1975[ISI][Medline].
24.
Greene, DA,
and
Lattimer SA.
Impaired rat sciatic nerve sodium-potassium ATPase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation.
J Clin Invest
72:
1058-1063,
1983[ISI][Medline].
25.
Greene, DA,
and
Latimer A.
Action of sorbinil in diabetic peripheral nerve.
Diabetes
33:
712-716,
1984[Abstract].
26.
Greene, DA,
Lattimer SA,
and
Sima AAF
Perspectives in diabetes: are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Diabetes
37:
688-693,
1988[Abstract].
27.
Greene, DA,
and
Mackway AM.
Decreased myo-inositol content and Na+-K+-ATPase in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
Diabetes
35:
1106-1108,
1986[Abstract].
28.
Guerrero, C,
Lecuona E,
Pesce L,
Ridge KM,
and
Sznajder JI.
Dopamine regulates Na-K-ATPase in alveolar epithelial cells via MAPK-ERK-dependent mechanisms.
Am J Physiol Lung Cell Mol Physiol
281:
L79-L85,
2001
29.
Hayashi, T,
Esaki T,
Muto E,
Kano H,
Asai Y,
Thakur N,
Jayachandran M,
and
Sumi D.
Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide.
Arterioscler Thromb Vasc Biol
20:
782-792,
2000
30.
Herrington, DM.
Dehydroepiandrosterone and coronary atherosclerosis.
Ann NY Acad Sci
774:
271-280,
1995[Abstract].
31.
Kim, J,
Kyriazi H,
and
Greene DA.
Normalization of Na+-K+-ATPase activity in isolated membrane fraction from sciatic nerves of streptozotocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro.
Diabetes
40:
558-567,
1991[Abstract].
32.
Lee, KH,
Finnigan-Bunick C,
Bahr J,
and
Bunick D.
Estrogen regulation of ion transporter messenger RNA levels in mouse efferent ductules are mediated differentially through estrogen receptor (ER) and ER
.
Biol Reprod
65:
1534-1541,
2001
33.
Liu, D,
and
Dillon JS.
Dehydroepiandrosterone activates endothelial cell nitric oxide synthase by a specific plasma membrane receptor coupled to Gai2,3.
J Biol Chem
277:
21379-21388,
2002
34.
Lou, MF,
Dickerson JE, Jr,
Garadi R,
and
York BM, Jr.
Glutathione depletion in the lens of galactosemic and diabetic rats.
Exp Eye Res
46:
517-530,
1988[ISI][Medline].
35.
Low, PA,
and
Nickander KK.
Oxygen free radical effects in sciatic nerve in experimental diabetes.
Diabetes
40:
873-877,
1991[Abstract].
36.
Mayer, JH,
and
Tomlinson DR.
Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or aldose reductase inhibitor in streptozotocin-diabetic rats.
Diabetologia
25:
433-438,
1983[ISI][Medline].
37.
Mihara, M,
Uchiyama M,
and
Fukuzama K.
Thiobarbituric acid value of fresh homogenate of rat as a parameter of lipid peroxidation in aging, CC14 intoxication, and vitamin E deficiency.
Biochem Med
23:
302-311,
1980[ISI][Medline].
38.
Miller, FJ,
Gutterman DD,
Rios CD,
Heistad DD,
and
Davidson BL.
Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis.
Circ Res
82:
1298-1305,
1998
39.
Nadal, A,
Diaz M,
and
Valverde MA.
The estrogen trinity: membrane, cytosolic, and nuclear factors.
News Physiol Sci
16:
251-255,
2001
40.
Narkar, V,
Hussain T,
and
Lokhandwala M.
Role of tyrosine kinase and p44/42 MAPK in D(2)-like receptor-mediated stimulation of Na+,K+-ATPase in kidney.
Am J Physiol Renal Physiol
282:
F697-F702,
2002
41.
Nestler, JE.
Dehydroepiandrosterone: fountain of youth or snake oil?
The Endocrinologist
7:
423-428,
1997[ISI].
42.
Nestler, JE,
and
McClanahan MA.
Diabetes and adrenal disease.
Baillieres Clin Endocrinol Metab
6:
829-847,
1992[ISI][Medline].
43.
Omawari, N,
Dewhurst M,
Vo P,
Mahmood S,
Stevens E,
and
Tomlinson DR.
Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium nitroprusside and evening primrose oil.
Br J Pharmacol
118:
186-190,
1996[Abstract].
44.
Pesce, L,
Guerrero C,
Comellas A,
Ridge KM,
and
Sznajder JI.
Beta-agonist regulate Na,K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways.
FEBS Lett
486:
310-314,
2000[ISI][Medline].
45.
Pieper, GM.
Review of alterations in endothelial nitric oxide production in diabetes.
Hypertension
31:
1047-1060,
1998
46.
Recknagel, RO,
and
Ghoshal AK.
Lipoperoxidation as a vector in carbon tetrachloride hepatotoxicity.
Lab Invest
15:
132-145,
1996.
47.
Regelson, W,
and
Kalimi M.
Dehydroepiandrosterone (DHEA)the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects Mechanism of action?
Ann NY Acad Sci
719:
564-575,
1994[ISI][Medline].
48.
Salom, JB,
Burguete MC,
Perez-Asensio FJ,
Torregrosa G,
and
Alborch E.
Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition.
J Cereb Blood Flow Metab
21:
422-429,
2001[ISI][Medline].
49.
Schwartz, AG,
and
Pashko LL.
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs.
J Cell Biochem
22:
210-217,
1995.
50.
Schwartz, AG,
and
Pashko LL.
Mechanism of cancer preventive action of DHEA. Role of glucose-6-phosphate dehydrogenase.
Ann NY Acad Sci
774:
180-186,
1995[ISI][Medline].
51.
Siman, CM,
and
Eriksson UJ.
Vitamin C supplementation of the maternal diet reduces the rate of malformation in the offspring of diabetic rats.
Diabetologia
40:
1416-1424,
1997[Medline].
52.
Tamagno, E,
Aragno M,
Boccuzzi G,
Gallo M,
Parola S,
Fubini B,
Poli G,
and
Danni O.
Oxygen free radical scavenger properties of dehydroepiandrosterone.
Cell Biochem Funct
16:
57-63,
1998[ISI][Medline].
53.
Teoh, H,
and
Man RY.
Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17beta-estradiol involves non-genomic mechanisms and the cyclic AMP cascade.
Br J Pharmacol
129:
1739-1747,
2000
54.
Terata, K,
Coppey LJ,
Davidson EP,
Dunlap JA,
Gutterman DD,
and
Yorek MA.
Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction.
Br J Pharmacol
128:
837-843,
1999
55.
Thompson, LP,
Pinkas G,
and
Weiner CP.
Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation.
Circulation
102:
445-451,
2000
56.
Tomlinson, DR.
The pharmacology of diabetic neuropathy.
Diabetes Metab Rev
8:
67-84,
1992[ISI][Medline].
57.
Tummala, S,
and
Svec F.
Correlation between the administered dose of DHEA and serum levels of DHEA and DHEA-S in human volunteers: analysis of published data.
Clin Biochem
32:
355-361,
1999[ISI][Medline].
58.
Vermeulen, A.
Dehydroepiandrosterone sulfate and aging.
Ann NY Acad Sci
719:
121-127,
1994.
59.
Ward, JD.
Biochemical and vascular factors in the pathogenesis of diabetic neuropathy.
Clin Invest Med
18:
267-274,
1995[ISI][Medline].
60.
Wellman, M,
Shane-McWhorter L,
Orlando PL,
and
Jennings JP.
The role of dehyroepiandrosterone in diabetes mellitus.
Pharmacotherapy
19:
582-591,
1999[ISI][Medline].
61.
Wichmann, U,
and
Wichmann G.
Serum levels of testosterone precursors, testosterone and estradiol in 10 animal species.
Exp Clin Endocrinol
83:
283-290,
1984[ISI][Medline].
62.
Young, W.
H2 clearance measurement of blood flow: a review of technique and polarographic principles.
Stroke
11:
552-564,
1980[Abstract].
63.
Zhang, Y,
and
Davidge ST.
Effect of estrogen replacement on vasoconstrictor responses in rat mesenteric arteries.
Hypertension
34:
1117-1122,
1999
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |